Business Context and Reporting Period
This Form 6-K filing by Therapix Biosciences Ltd. (not Scisparc Ltd.) covers the month of June 2017. The report discloses changes to the composition of the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Resignations: On June 28, 2017, Donald P. Dizon and David Silverman resigned from the Board of Directors.
- Reason for Resignation: The resignations were not related to any disagreement with the Board regarding operations, policies, or practices.
- Appointment: On June 28, 2017, the Board appointed Eric So to fill the vacancy created by Mr. Dizon's resignation, effective immediately.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It confirms no undisclosed arrangements or material interest transactions exist regarding the appointment of Mr. So.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following the June 28, 2017 changes.
- Confirm that the resignations of Mr. Dizon and Mr. Silverman were voluntary and unrelated to company disputes.
- Note that this filing contains no financial performance data for the period.